GlassScriptPhysician profile
Lisa Michel Stone
NPI 1235105875
$2,831.84
in general payments reported to CMS, 2019-2025
24 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $33.83 · 2022: $131 · 2023: $846 · 2024: $991 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,099.81 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $292.29 | 2020-2025 | Stelara, Tremfya, Simponi |
| Qol Medical, LLC | $280.73 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $198.05 | 2022-2025 | |
| Celgene Corporation | $154.34 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $146.32 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.13 | 2023-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $96.31 | 2023-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $76.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $61.30 | 2023 | Dupixent |
| Amgen INC. | $45.66 | 2023 | Avsola, Amjevita |
| Organon LLC | $43.89 | 2024-2025 | Renflexis, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $30.45 | 2025 | Sotyktu |
| Ardelyx, INC. | $26.95 | 2025 | Ibsrela |
| Pfizer INC. | $23.91 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $23.40 | 2023 | Rebyota |
| Lilly USA, LLC | $19.85 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $19.23 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $17.83 | 2023 | Linzess |
| Currax Pharmaceuticals LLC | $16.95 | 2024 | Contrave |
| Pharmacosmos Therapeutics INC. | $16.32 | 2025 | Monoferric |
| Fresenius Kabi USA, LLC | $15.82 | 2024 | Idacio |
| Evoke Pharma, INC. | $14.38 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.